Item 8.01. Other Events.

On November 20, 2019, CNS Pharmaceuticals, Inc. (the "Company") closed the issuance of an additional 318,750 shares of its common stock pursuant to the exercise in full of the underwriters' over-allotment option in connection with its initial public offering (the "IPO"). The additional shares were sold at the IPO price of $4.00 per share, before underwriting discounts and commissions. The gross proceeds from the sale of the additional shares, before deducting underwriting discounts and commissions, was $1.3 million, bringing the total gross proceeds from the IPO to $9.8 million. A copy of the press release announcing the closing of the over-allotment option is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits



  Exhibit No. Exhibit Description

  99.1          Press release dated November 21, 2019


































































  2

© Edgar Online, source Glimpses